|
|
The findings and conclusions in these presentations have not been formally disseminated by the Centers for Disease Control and Prevention and should not be construed to represent any agency determination or policy. |
Clearwater
| |||
A8: HPV vaccine - Information for development of recommendations and vaccine implementation | |||
| Learning Objectives: By the end of the session, participants will understand the epidemiology of HPV and the burden of HPV disease in the US, the process for developement of vaccine recommendations and program considerations for introduction of vaccine
| |||
| Moderator: | Lauri Markowitz | ||
| 10:00 AM | Introduction -- Lauri Markowitz | ||
| 10:20 AM | 41 | Overview of HPV epidemiology Eileen F. Dunne | |
| 10:40 AM | 40 | Update on HPV vaccine and development of vaccine recommendations Lauri E. Markowitz | |
| 11:00 AM | 42 | Cost effectiveness models of HPV vaccines Harrell W. Chesson | |
| 11:20 AM | 43 | National survey of pediatricians' knowledge, beliefs and perceived barriers to HPV vaccination Nicole Liddon | |
| 11:40 AM | 44 | Collaborative efforts in California to prepare for HPV vaccine Heidi Bauer | |